December 2025 – Page 4

Padcev-Keytruda Combination Succeeds Again in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

1 month ago talkbio0Tagged EV-304, Event-Free Survival, KEYNOTE-B15, Keytruda, Malignant neoplasm of urinary bladder, Padcev

Padcev; Keytruda; bladder cancer; KEYNOTE-B15; EV-304; event-free survival

Jim Lang Appointed to the Board of Directors of Halozyme Therapeutics

1 month ago talkbio0Tagged Appointments, Bench International, Biological Factors, BioVie, board of directors, Corporate governance, drug delivery platform, election, Halozyme Therapeutics, Jim Lang

Jim Lang; Halozyme Therapeutics; Board of Directors; appointment; election; Bench International; biopharmaceutical; drug delivery platform; corporate governance; OptimizeRx; BioVie

Models are out, molecules are in as AI drug startups sprint to the clinic

1 month ago talkbio0Tagged Absci, AI drug discovery, AI-designed molecules, Clinical Trials, clinical-stage AI startups, Funding, Insilico Medicine, PsiThera, Recursion Pharmaceuticals, small molecule therapeutics

AI drug discovery; AI-designed molecules; clinical-stage AI startups; small-molecule therapeutics; biotech funding; Insilico Medicine; Recursion Pharmaceuticals; Absci; PsiThera; clinical trials

FDA Commissioner Makary Addresses COVID-19 Vaccine Safety Concerns Amid Internal Debates and Investigations

1 month ago talkbio0Tagged Cautionary Warning, COVID19 (disease), Marty Makary, mRNA Vaccines, Myocarditis, RFK gene, Safety, United States Food and Drug Administration, vaccine deaths, Vaccines

Marty Makary; FDA; COVID-19 vaccine; myocarditis; vaccine deaths; safety warnings; RFK Jr.; mRNA vaccines

Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb

1 month ago talkbio0Tagged biobucks, Burning Mouth Syndrome, China, Clinical Trials, global strategic collaboration, Harbour BioMed, Harbour Mice ® technology, Immunology, License Agreement, milestones, multi-specific antibodies, Myers Squibb, Neoplasms

Harbour BioMed; Bristol Myers Squibb; BMS; multi-specific antibodies; $90 million upfront; $1.035 billion milestones; global strategic collaboration; license agreement; Harbour Mice technology; immunology; oncology; biobucks deal; China early clinical trials

Berkeley startup raises $106.5M for all‑RNA ‘jumping gene’ therapies

1 month ago talkbio0Tagged Berkeley, Cells, Funding, gene therapy, jumping gene, M financing, programmable RNA medicines, Radar Therapeutics, RNA gene, Series A

Radar Therapeutics; Berkeley startup; $106.5M financing; Series A; jumping gene; RNA gene insertion; programmable RNA medicines; cell and gene therapy; biotech funding

Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites

1 month ago talkbio0Tagged 2025, Acquisition, Acquisitions, fibroblast growth factor 21, Health care facility, Johnson & Johnson Intra-Cellular, M&A, MASH, Merck Verona, Patent Cliff, Pharma, pharma patent expirations, Sanofi Blueprint Medicines

pharma M&A 2025; biotech acquisitions; patent cliff; pharma patent expirations; Novo Nordisk Akero deal; Johnson & Johnson Intra-Cellular acquisition; Merck Verona Pharma deal; Sanofi Blueprint Medicines acquisition; FGF21 MASH deals; 2025 healthcare deals

Nektar Digs Into Mid-Stage Data To Establish Alopecia Efficacy of Rezpeg

1 month ago talkbio0Tagged Alopecia, Autoimmune Diseases, Effectiveness, eli lilly, IL-2 pathway, mid-stage trial, Nektar Therapeutics, Phase 3 planning, REZOLVE-AA, Rezpeg, Rezpegaldesleukin, SALT score * *, Signal

Nektar Therapeutics; rezpegaldesleukin; Rezpeg; REZOLVE-AA; Phase 2b; alopecia areata; hair loss; SALT score; mid-stage trial; efficacy signal; Eli Lilly; IL-2 pathway; autoimmune disease; Phase 3 planning

RTW-backed startup Yarrow Bioscience signs autoimmune antibody deal with China’s GenSci

1 month ago talkbio0Tagged anti-TSHR antibody, Antibodies, Autoimmune, Changchun GeneScience Pharmaceutical, China, GenSci, GS-098, Investments, RTW, strategic partnership, Thyroid associated opthalmopathies, Yarrow Bioscience, YB-101

RTW Investments; Yarrow Bioscience; GenSci; Changchun GeneScience Pharmaceutical; autoimmune; antibody; GS-098; YB-101; anti-TSHR antibody; thyroid eye disease; China; ex-China rights; strategic partnership; licensing deal

Ambros Therapeutics launches with $125M to develop non-opioid chronic pain drug neridronate

1 month ago talkbio0Tagged * * Vivek Ramaswamy * *, 6-amino-1-hydroxyhexane-1,1-diphosphonate, Ambros Therapeutics, Analgesics, Non-Narcotic, Chronic pain, Complex Regional Pain Syndromes, CRPS-1, Diphosphonates, Series A

Ambros Therapeutics; $125 million Series A; chronic pain; complex regional pain syndrome type 1; CRPS-1; neridronate; non-opioid analgesic; bisphosphonate; Vivek Ramaswamy; biotech financing